JOURNAVX met the primary endpoint by demonstrating statistically significant superior reduction in pain vs placebo. 1,b JOURNAVX did not meet the first key secondary endpoint that hypothesized ...
Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (p24) subunits in hexamers. Surface plasmon resonance sensorgrams ...
Lefamulin 150mg (in 15mL of 0.9% sodium chloride); per vial; soln for IV infusion after dilution. Xenleta is a systemic pleuromutilin antibacterial that inhibits bacterial protein synthesis through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback